Search - tctmd.com

Displaying 821 - 840 of 900

Sort: Relevancy | Date

Presentation

Ticagrelor vs. Clopidogrel in Patients with ACS and a History of Stroke or TIA

Presenter: Stefan K. James

May 31, 2012

Presentation TCT Russia 2012

Acute Care Approch to PCI Intervention: the Interventional Phamacology Menu

Presenter: Pawel Buszman

May 28, 2012

Presentation

Mortality Benefit with Prasugrel in the TRITON-TIMI 38 CABG Cohort

Presenter: 195949|Peter Smith

May 25, 2012

Presentation

Influence of Genetic Polymorphisms on High- and Standard-Dose Clopidogrel After PCI

Presenter: Matthew J. Price

May 22, 2012

Presentation EuroPCR 2012

ROMA II Reload

Presenter: G. Sardella

May 17, 2012

Presentation TCT Mediterranean 2012

Anticoagulation in ACS: Role of Bivalirudin

Presenter: Gregg W. Stone

May 04, 2012

Presentation

PHARAOH: Effect of A Priori vs. Provisional Heparin on Radial Artery Occlusion After Transradial Coronary Angiography and Patent Hemostasis

Presenter: Samir B. Pancholy

April 26, 2012

Presentation TCTAP 2012

P2Y12 Receptor Inhibitors: Which Drug and for Whom?

Presenter: Cheol Whan Lee

April 26, 2012

Presentation TCTAP 2012

Evidence-Based Pharmacotherapy Recommendations for PCI, NSTEMI, and STEMI:

Presenter: Gregg W. Stone

April 26, 2012

Presentation

Accelerated Platelet Inhibition by Switching from Atorvastatin to a Non-CYP3A4-Metabolized Statin

Presenter: Y. Park

April 24, 2012

$Unfractionated, Low Molecular Weight Heparins, and Xa Inhibitors in ACS and PCI, With and Without GP IIb/IIIa Inhibitors$

Presentation Fellows 2012

Unfractionated, Low Molecular Weight Heparins, and Xa Inhibitors in ACS and PCI, With and Without GP IIb/IIIa Inhibitors

Presenter: George Dangas

April 22, 2012

Presentation Fellows 2012

Platelet Function Testing, Genomics, and Antiplatelet Agent Resistance

Presenter: Deepak Bhatt

April 22, 2012

Presentation Fellows 2012

Oral Antithrombin and Xa Inhibitors for ACS and PCI

Presenter: Michael Ezekowitz

April 22, 2012

Presentation Fellows 2012

Oral Antiplatelet Agents in PCI and ACS

Presenter: Roxana Mehran

April 22, 2012

Presentation Fellows 2012

Bivalirudin in ACS and PCI

Presenter: Gregg Stone

April 22, 2012

Presentation

A Randomized Trial of Prasugrel vs. Clopidogrel in Patients with High Platelet Reactivity on Clopidogrel After Elective PCI with DES

Presenter: Dietmar Trenk

April 18, 2012

Presentation GI2 2012

Dual Antiplatelet Therapy Post PCI: Challenging the Guidelines

Presenter: Fausto Feres

April 13, 2012

Presentation

Relationship Between CYP2C19 Polymorphisms and Ischemic and Bleeding Outcomes in Stable Outpatients

Presenter: Deepak L. Bhatt

April 09, 2012

Presentation

Does Aggressive Statin Therapy Reduce Coronary Atherosclerotic Plaque Lipid Content?

Presenter: Annapoorna S. Kini

April 04, 2012

Presentation

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

Presenter: Marco Valgimigli

April 02, 2012

Advertisement

Ticagrelor vs. Clopidogrel in Patients with ACS and a History of Stroke or TIA

Acute Care Approch to PCI Intervention: the Interventional Phamacology Menu

Mortality Benefit with Prasugrel in the TRITON-TIMI 38 CABG Cohort

Influence of Genetic Polymorphisms on High- and Standard-Dose Clopidogrel After PCI

ROMA II Reload

Anticoagulation in ACS: Role of Bivalirudin

PHARAOH: Effect of A Priori vs. Provisional Heparin on Radial Artery Occlusion After Transradial Coronary Angiography and Patent Hemostasis

P2Y12 Receptor Inhibitors: Which Drug and for Whom?

Evidence-Based Pharmacotherapy Recommendations for PCI, NSTEMI, and STEMI:

Accelerated Platelet Inhibition by Switching from Atorvastatin to a Non-CYP3A4-Metabolized Statin

Unfractionated, Low Molecular Weight Heparins, and Xa Inhibitors in ACS and PCI, With and Without GP IIb/IIIa Inhibitors

Platelet Function Testing, Genomics, and Antiplatelet Agent Resistance

Oral Antithrombin and Xa Inhibitors for ACS and PCI

Oral Antiplatelet Agents in PCI and ACS

Bivalirudin in ACS and PCI

A Randomized Trial of Prasugrel vs. Clopidogrel in Patients with High Platelet Reactivity on Clopidogrel After Elective PCI with DES

Dual Antiplatelet Therapy Post PCI: Challenging the Guidelines

Relationship Between CYP2C19 Polymorphisms and Ischemic and Bleeding Outcomes in Stable Outpatients

Does Aggressive Statin Therapy Reduce Coronary Atherosclerotic Plaque Lipid Content?

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content